ProMIS Neurosciences Inc. Common Shares (ON) (PMN)
ProMIS Neurosciences Inc. is a biotechnology company focused on developing precision medicines for neurodegenerative diseases. Utilizing its proprietary platforms, the company researches and develops antibody-based therapies targeting misfolded proteins involved in conditions such as Alzheimer’s disease and other neurodegenerative disorders. Headquartered in Toronto, Ontario, ProMIS aims to advance treatments that can modify disease progression and improve patient outcomes.
Company News
ProMIS Neurosciences secured $3 million in private financing through a PIPE offering, with an additional $9 million from warrant exercises, totaling approximately $12 million in gross proceeds to advance clinical development of PMN310 and support corporate operations.
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms. Ultragenyx Pharmaceutical shares dipped 9.4% to $42.46 on Monday. Here are...